COVID-19, caused by SARS-CoV-2, lacks effective therapeutics. Additionally, no antiviral
drugs or vaccines were developed against the closely related coronavirus, SARS-CoV-1 or …

In fragment-based drug discovery (FBDD), there is a developing appreciation that 3D fragments
could offer opportunities that are not provided by 2D fragments. This review provides an …

Fragment‐based drug discovery is now widely adopted for lead generation in the pharmaceutical
industry. However, fragment screening collections are often predominantly populated …

Fragment-based drug discovery (FBDD) has grown into a well-established approach in the
pursuit of new therapeutics. Key to the success of FBDD is the low molecular complexity of …

Fragment‐based drug discovery (FBDD) has a growing need for unique screening libraries.
The cyclobutane moiety was identified as an underrepresented yet attractive three‐…

Pyrrolobenzodiazepines (PBDs) and their dimers (bis-PBDs) have emerged as some of the
most potent chemotherapeutic compounds, and are currently under development as novel …

Pyrrolobenzodiazepines (PBDs) and their dimers (bis-PBDs) have emerged as some of the
most potent chemotherapeutic compounds and are currently under development as novel …

Surface plasmon resonance (SPR) biosensor methods are ideally suited for fragment-based
lead discovery. However, generally applicable experimental procedures and detailed …

Fragment-based drug discovery is now widely adopted for lead generation in the pharmaceutical
industry. However, fragment screening collections are often predominantly populated …

Hyponatraemia is well recognised in hypothyroidism, especially in the severe forms. The
hypothyroidism is usually primary, but there are reports of hyponatraemia in patients with …